Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Dexamethasone 7Bortezomib 4Lenalidomide 3pomalidomide 2glucarpidase 2Kidney Transplantation 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1osimertinib 1mirabegron 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Zoledronic Acid 1Urinalysis 1Topotecan 1Thalidomide 1Tablets 1Stents 1Sitagliptin Phosphate 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency × Thalidomide × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡